Page 5 - Scientific Library

PD-1:PD:-L1 immune checkpoint pathway targeting immunotherapies have shown great potential for many cancer patients. Recently, The FDA has granted accelerated approval to the immunotherapy drug pembrolizumab

As discussed previously in our recent Drug Discovery post, Immunotherapy is one of the central research fields for various disease treatments and also certain cancers. A major regulator of immune homoeostasis

As a regulator of the immune system, Immune checkpoints appear to be privileged targets In Drug Discovery and Immunotherapy

Focus Biomolecules produces a broad range of bioactive lipid mediators as well as many small molecule inhibitors of numerous lipid metabolic pathways for use as cellular probes.  These can be supplied

Over the last several years, the Immune System has appeared as a central, priority target to fight cancer and various other diseases. Currently, in cancer

Recently, BPS Bioscience have released a new Adenosine A2A Receptor (A2AR / ADORA2A) Functional Recombinant Cell Line for screening A2AR agonists and antagonists. An excellent means to efficiently evaluate

Over the last years, mRNA-based experimental approaches have been successfully used in a broad range of research applications (genome editing, gene replacement, vaccine, immunotherapy, cellular reprogramming...)

Cell-Based ELISA tests now enable precise measurement of the phosphorylation status or expression profiles of target proteins (biomarkers) in whole cells. In this post, a review of high performing cell-based

Since the discovery of reprogramming factors in 2006 and the boom of CRISPR gene editing strategies, induced pluripotent stem cells (iPSC) have emerged as new cellular models. The development of 3D cell

As mentioned in a previous post the DAX Biochips from AIM Biotech are an innovative and versatile microfluidic platform, allowing researchers to more easily develop 3D cell culture models, to work as close

Immune checkpoint molecules play an important role in T cell functionality after TCR/MHC signalling. Blockade of two B7/CD28 family checkpoint molecules, CTLA-4 and PD-1, have already demonstrated excellent

For many pathologies such as cancer or neurological disorders, it has been found that Histone Deacetylase (HDAC) activity is disrupted, making them promising targets for drug development. Scientists